QIAGEN partners with U.K. to expand biomarker research in Manchester
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with multiple organizations to sup…
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with multiple organizations to sup…
. - New web-based product delivers fast and high-confidence interpretation and reporting of variants from next-generati…
. - Mount Sinai collaboration with QIAGEN Center of Excellence in Biological Interpretation demonstrates translational…
. - Molecular testing of biofluids promises unprecedented access to gene mutations, gene expression signatures and expr…
. - FGFR-TACC fusion genes, the target of potential targeted therapies for glioblastoma and other cancers, rights acqui…
. Achieves Q1 2013 targets: Net sales of $303.6 million grow 3% CER on expansion in all regions; adjusted diluted EPS…
. - Point-of-Care Diagnostics Initiative is part of Grand Challenges in Global Health program funded by Bill & Melinda…
. - Growing healthcare and research sectors drive India's need for molecular diagnostics and testing technologies for a…
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and Celera Corporation (NASDAQ:CRA) today announced an agreeme…
QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced the results of operations for the fourth quar…